National Institute on Drug Abuse

NIDA's director, Nora Volkow, sets overall research priorities in consultation with the NIH director. Actual grant funding is allocated through a rigorous peer-review process run by the Center for Scientific Review, not through Volkow's unilateral decisions. NIDA does not operate as an investment firm; its capital deployment is driven by scientific merit and public-health needs.

NIDA primarily sources proposals through open competitive funding announcements (RFAs and PARs) published on grants.nih.gov. Scientists at academic medical centers, research institutions, and small businesses submit applications; those with the highest scores after peer review are funded. NIDA also supports an intramural research program at its own labs in Baltimore and Bethesda.

NIDA is a grant-making federal agency, not an investment firm. It does not take equity in private companies. However, its Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs do fund for-profit startups developing products for addiction treatment, with the NIH sharing in royalty revenues.

NIDA avoids funding research on drugs of abuse that are not linked to public-health priorities — for example, most clinical research on hallucinogens for psychiatric applications is under NIMH or other agencies. NIDA also does not fund studies focused on performance-enhancing drugs (anabolic steroids) except where they intersect with substance-use disorders.

Yes. NIDA routinely co-funds initiatives with the National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Cancer Institute (NCI), and the National Institute of Mental Health (NIMH). It also partners with the CDC on drug-overdose surveillance and with the DEA on scheduling decisions.

At roughly $1.5B annually, NIDA's budget is comparable to a mid-size private family office's AUM — but it is deployed entirely as grants with no expectation of financial return. Unlike a family office, NIDA's capital has a public-health return on investment goal, and its funding horizon is indefinite, tied to congressional appropriations.

NIDA's funding comes from the U.S. federal government, allocated through the NIH appropriation by Congress. It is part of the Department of Health and Human Services. The agency does not accept private donations or endowment-style gifts.